Intensity Therapeutics (INTS) Other Non Operating Income (2022 - 2026)
Intensity Therapeutics' (INTS) quarterly Other Non Operating Income came in at -$2000.0 in Q1 2026, down 106.25% YoY from $32000.0 in Q1 2025, and down 300.0% on a QoQ basis from $1000.0 in Q4 2025.
Intensity Therapeutics (INTS) Other Non Operating Income (2022 - 2026) Analysis & Trends
Intensity Therapeutics (INTS) has 5 years of Other Non Operating Income data on file, last reported at -$2000.0 in Q1 2026.
- Quarterly Other Non Operating Income fell 106.25% year-over-year to -$2000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $153000.0 (up 337.14% YoY) and the FY2025 annual result came in at $186000.0, up 6100.0% from the prior year.
- Other Non Operating Income eased to -$2000.0 in Q1 2026, from $1000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $2.3 million in Q4 2023 to a low of -$47646.0 in Q4 2022.
- A 5-year average of $188874.8 and a median of $4000.0 in 2023 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2023 — Other Non Operating Income jumped 4897.88% — and 2026, when it sank 106.25%.
- Tracing INTS's Other Non Operating Income over 5 years: stood at -$47646.0 in 2022, then jumped by 4897.88% to $2.3 million in 2023, then sank by 100.26% to -$6000.0 in 2024, then soared by 116.67% to $1000.0 in 2025, then slumped by 300.0% to -$2000.0 in 2026.
- The last three Other Non Operating Income figures came in at -$2000.0 (Q1 2026), $1000.0 (Q4 2025), and $3000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Intensity Therapeutics | 13.06 Mn | 13.06 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Sep 30, 2025 | 3,000.00 |
| Jun 30, 2025 | 151,000.00 |
| Mar 31, 2025 | 32,000.00 |
| Dec 31, 2024 | -6,000.00 |
| Sep 30, 2024 | 9,000.00 |
| Dec 31, 2023 | 2.29 Mn |
| Jun 30, 2023 | 4,000.00 |
| Mar 31, 2023 | 1,000.00 |
| Dec 31, 2022 | -47,646.00 |
| Sep 30, 2022 | 7,118.00 |
| Jun 30, 2022 | 16,900.00 |